pharma-congress-molecular-medicine-2018-posters

Page 46

O c t o b e r 1 9 - 2 0 , 2 0 1 8 | T o k y o , J a p a n

Pharma Congress 2018 & Molecular Medicine 2018

& Psychiatric Disorders 2018

Asian Journal of Biomedical and Pharmaceutical Sciences

ISSN: 2249-622X

Volume 8

International Conference on

PHARMACEUTICS AND NOVEL DRUG DELIVERY SYSTEMS

International Conference on

CELLULAR AND MOLECULAR MEDICINE

Annual Congress on

PSYCHIATRY AND PSYCHIATRIC DISORDERS

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C3-009

THE ACCESS TO PRODUCE COMPATIBLE VIRAL VACCINES FOR

INDIVIDUALITY

Tirasak Pasharawipas

Rangsit University, Thailand

here is a question why viral vaccines cannot be effective for everybody. This is a question that we need to revise our knowl-

edge and manipulate in the right direction for the viral vaccine production. To prevent a viral infection, a body must produce

a protective antibody to prevent the viral particle to attach the viral receptor on a target cell. Theoretically, adaptive immunity

needs induction not only by an antigen but also our cellular molecule called major histocompatibility complex (MHC) to form a

complex molecule with its appropriate epitope to activate a specific receptor of T cell. There are two classes of MHC molecules

called class I and class II. MHC class I is required for inducing cytotoxic T cell while MHC class II is for helper T cell. Helper T

cell plays a key role to induce an effective stage of acquired immunity including a specific protective antibody. To produce the

viral-specific antibody, MHC class II plays a key role to induce helper T cell and then B cell to synthesize a specific antibody. Since

the MHC gene alleles are highly polymorphic so the possibility that individuals have the same gene alleles might be one in a

million which, mostly, can be found in those who are an identical twin. Accordingly, a subunit viral vaccine, which contains a limit

number of epitopes, would reduce a capacity of an antigen presenting cell, such as a dendritic cell, to process some epitopes

to induce the helper T cell clones. Subsequently, in some people, the corresponding B cell clones cannot synthesize the specific

antibody to neutralize the infectious viral particle. Accordingly, this presentation will present the novel approach to develop the

viral vaccine for everybody.